GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

pozelimab   Click here for help

GtoPdb Ligand ID: 12900

Synonyms: pozelimab-bbfg | REGN-3918 | REGN3918 | Veopoz®
Approved drug Immunopharmacology Ligand
pozelimab is an approved drug (FDA (2023))
Compound class: Antibody
Comment: Pozelimab (REGN-3918) targets the terminal complement component C5 [1]. It is designed to inhibit complement pathway activation and complement-mediated inflammatory tissue damage.
Selectivity at ligand targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
complement C5 Hs Antibody Binding 9.6 pKd - 1
⤷ pKd 9.6 (Kd 2.6x10-10 M) [1]
complement C5 Monkey Antibody Binding 8.1 pKd - 1
⤷ pKd 8.1 (Kd 8.55x10-9 M) [1]